Activity landscape of DNA methyltransferase inhibitors bridges chemoinformatics with epigenetic drug discovery

被引:18
|
作者
Jesus Naveja, J. [1 ,2 ]
Medina-Franco, Jose L. [1 ]
机构
[1] Univ Nacl Autonoma Mexico, Dept Farm, Fac Quim, Mexico City 04510, DF, Mexico
[2] Univ Nacl Autonoma Mexico, PECEM, Fac Med, Mexico City 04510, DF, Mexico
关键词
activity cliffs; cancer; data mining; DNA methyltransferase; epi-informatics; structure-activity relationships; CONSENSUS-ACTIVITY-CLIFFS; CANCER; METHYLATION; SIMILARITY; TARGETS; PREDICTION; DOCKING; MAPS;
D O I
10.1517/17460441.2015.1073257
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Activity landscapes are valuable tools for exploring systematically the structure-activity relationships (SAR) of chemical databases. Their application to analyze the SAR of DNA methyltransferase (DNMT) inhibitors, which are attractive compounds as potential epi-drugs or epi-probes, provides useful information to identify pharmacophoric regions and plan the development of predictive models and virtual screening. Areas covered: This paper highlights different approaches for conducting SAR analysis of datasets with a particular focus on the activity landscape methodology. SAR information of DNMT inhibitors (DNMTi), stored in a public database, is surveyed to further illustrate concepts and generalities of activity landscape modeling with a special emphasis on structure-activity similarity (SAS) maps. Expert opinion: The increasing SAR information reported for DNMTi opens up avenues to implement activity landscape methods. Despite several activity landscape methods, such as SAS maps, being well established, these need further refinement. For instance, novel combinations of multiple representations, such as the addition of Z-values of similarity (fusion-Z), lead to more robust representations of consensus SAS maps. Density SAS maps improve the visualization of the SAR. A survey of activity cliffs (i.e., pairs of compounds with high structural similarity but high differences in potency) of DNMTi available in a public database suggest that it is feasible to develop predictive models for non-nucleoside DNMTi using approaches such as quantitative structure-activity relationships and that non-nucleoside DNMTi in ChEMBL can be used as query molecules in similarity-based virtual screening.
引用
收藏
页码:1059 / 1070
页数:12
相关论文
共 50 条
  • [21] Modulation of the Immune System by Epigenetic Therapy: A Rationale for Combined Use of DNA Methyltransferase Inhibitors and Immune Checkpoint Inhibitors
    Kirsten, Gronbaek
    Orskov, A. D.
    Ohtani, H.
    Treppendahl, Marianne
    Liu, M.
    Hansen, J. W.
    Saini, S. K.
    Baylin, S. B.
    O'Connell, Casey
    Liang, G.
    Hadrup, S. R.
    Jones, P. A.
    ANNALS OF HEMATOLOGY, 2017, 96 : S46 - S47
  • [22] Improving drug discovery using image-based multiparametric analysis of the epigenetic landscape
    Farhy, Chen
    Hariharan, Santosh
    Ylanko, Jarkko
    Orozco, Luis
    Zeng, Fu-Yue
    Pass, Ian
    Ugarte, Fernando
    Forsberg, E. Camilla
    Huang, Chun-Teng
    Andrews, David W.
    Terskikh, Alexey V.
    ELIFE, 2019, 8
  • [23] Epigenetic reprogramming in cloned mouse embryos following treatment with DNA methyltransferase and histone deacetylase inhibitors
    Zarei, Maryam
    Shamaghdari, Boshra
    Vahabi, Zeinab
    Dalman, Azam
    Eftekhari Yazdi, Poopak
    SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE, 2022, 68 (03) : 227 - 238
  • [24] Epigenetic therapy in cancer: Molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors
    Schneider-Stock, Regine
    Ocker, Matthias
    IDRUGS, 2007, 10 (08) : 557 - 561
  • [25] Discovery of Inhibitors of DNA Methyltransferase 2, an Epitranscriptomic Modulator and Potential Target for Cancer Treatment
    Schwickert, Marvin
    Fischer, Tim R.
    Zimmermann, Robert A.
    Hoba, Sabrina N.
    Meidner, J. Laurenz
    Weber, Marlies
    Weber, Moritz
    Stark, Martin M.
    Koch, Jonas
    Jung, Nathalie
    Kersten, Christian
    Windbergs, Maike
    Lyko, Frank
    Helm, Mark
    Schirmeister, Tanja
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (14) : 9750 - 9788
  • [26] DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences
    Thomas, Xavier
    EXPERT OPINION ON DRUG DISCOVERY, 2012, 7 (11) : 1039 - 1051
  • [27] DNA Methyltransferase 3A: A Significant Target for the Discovery of Inhibitors as Potent Anticancer Drugs
    Feng, Qixun
    Duan, Honggao
    Zhou, Xinglong
    Wang, Yuning
    Zhang, Jinda
    Zhang, Haoge
    Chen, Guoliang
    Bao, Xuefei
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2024, 24 (05) : 507 - 520
  • [28] Epigenetic Regulation of Host Defense Peptide Synthesis: Synergy Between Histone Deacetylase Inhibitors and DNA/Histone Methyltransferase Inhibitors
    Whitmore, Melanie A.
    Li, Hong
    Lyu, Wentao
    Khanam, Sharmily
    Zhang, Guolong
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [29] Recent Advances in Small-Molecule Modulation of Epigenetic Targets: Discovery and Development of Histone Methyltransferase and Bromodomain Inhibitors
    Sweis, Ramzi F.
    Michaelides, Michael R.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 48, 2013, 48 : 185 - 203
  • [30] Discovery and structure-based optimization of novel allosteric inhibitors targeting the epigenetic methyltransferase PRC2
    Lingel, Andreas
    Bussiere, Dirksen
    Cantwell, John
    Dillon, Michael
    Huang, Ying
    Lindvall, Mika
    Sendzik, Martin
    Shu, Wei
    Taft, Benjamin
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252